Twist Bioscience Corp Overview
Industry: Diagnostics & Research
Sector: Healthcare
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools f
Research snapshot
Latest filing date 2026-08-03This Mavefund research page organizes verified information for Twist Bioscience Corp (TWST), including the company profile, price history, source-linked filings, available financial statements, research signals, and risks to review.
- Listing
- TWST · Nasdaq · MIC XNAS
- Country
- United States
- Trading currency
- USD
- Industry
- Diagnostics & Research
- Financial coverage
- Annual and interim statements available
- Latest filing source
- SEC EDGAR · filed 2026-08-03
- Latest SEC EDGAR filing Filed 2026-08-03
- Registration filing
Coverage is refreshed automatically and published only after data-integrity validation. Research support only; not personalized financial advice.
Mavefund brings filings, fundamentals, valuation, price history and news for Twist Bioscience Corp into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $118.4M (reported). Adjusted EBITDA was -$11.3M (+42% YoY).
What changed
- Revenue reported to $118.4M.
- Adjusted EBITDA +42% YoY to -$11.3M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Guggenheim reiterates Twist Bioscience stock rating on AI drug discovery potential
Headline from Investing.com: Guggenheim reiterates Twist Bioscience stock rating on AI drug discovery potential.
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now) (NASDAQ:TWST)
Headline from Seeking Alpha: Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now) (NASDAQ:TWST).
Twist Bioscience stock hits 52-week high at 143.1 USD
Headline from Investing.com: Twist Bioscience stock hits 52-week high at 143.1 USD.
Twist Bioscience files prospectus supplement for Invenra share resale By Investing.com
Headline from Investing.com South Africa: Twist Bioscience files prospectus supplement for Invenra share resale By Investing.com.
Twist Bioscience files prospectus supplement for Invenra share resale
Headline from Investing.com: Twist Bioscience files prospectus supplement for Invenra share resale.
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
Headline from Benzinga: Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported filing facts, organized and linked to the original source.
Source details load with the filing data. Values are standardized company disclosures for research support, not personalized financial advice.